• Phare
  • Validé par KD/KO

Anticorps Recombinant de lapin anti-HER2/ErbB2,p185-Specific

HER2/ErbB2,p185-Specific Recombinant Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

CloneNo.

240802C2

N° de cat : 84046-1-PBS

Synonymes

ERBB2, 240802C2, CD340, HER 2, HER 2/neu



Informations sur le produit

84046-1-PBS cible HER2/ErbB2,p185-Specific dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Peptide
Nom complet v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
Masse moléculaire calculée 138 kDa
Poids moléculaire observé185 kDa
Numéro d’acquisition GenBankBC167147
Symbole du gène HER2/ErbB2
Identification du gène (NCBI) 2064
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Protein A purfication
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signaling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.

{{ptg:RelatedPrimaryAntibodies}}